The story as far as the long quiet of the 1970s and 1980s is told in From Sacrament to Contraband. This volume takes it up from there and carries it to the present autumn. The subject is recent, and many of the institutions in it are still writing their own histories, so we have taken care to say when a claim is an institution's description of itself.
A Pharmacologist and a Cactus
The laboratory study of visionary plants is usually dated to 1897, when a German pharmacologist published the first systematic study of a naturally occurring visionary substance: the principal alkaloid of the peyote cactus, which he had isolated and which came to be called mescaline. Attested Among his methods was to take it himself. Attested
Nearly a century later, a small research institute would take his name. We read the choice as a statement of intent. Its founders wished to stand in the line of careful pharmacology, and not in the line of the counterculture that had made the whole subject untouchable.
The Builders of the Long Quiet
After the prohibitions of the late 1960s, lawful research came almost to a halt. What brought it back was not, at first, a great university or a drug company. It was a handful of small nonprofit organizations, founded by people who believed the questions were too important to abandon and who were prepared to spend decades on permits, protocols, and fundraising. Attested
- 1986. An association for psychedelic studies is founded in the United States to return these substances to lawful use through research, education, and changes in policy. It went on to sponsor the long series of trials of MDMA-assisted therapy for post-traumatic stress, and it now states that it aims to end drug prohibition everywhere. Attested
- 1993. A small scientific institute is incorporated in New Mexico by a group of scientists and psychiatrists, and named for the pharmacologist of 1897. It set out to help design, review, and fund rigorous studies of psilocybin and its relatives at established research institutions in the United States and Europe. It allows none of its grants to be spent on a university's overhead. Attested
- 1998. A foundation for psychedelic research and drug policy reform is founded in England. The chemist who first made LSD served on its scientific advisory board until his death in 2008. Attested
- 2007 and 2010. A European foundation for psychedelic research is founded in 2007. In 2010 a former chair of the British government's advisory council on drug misuse founds an independent scientific charity devoted to honest evidence about drugs of every kind. Attested
- Since then. Similar associations and research nonprofits have formed in Canada, Australia, Germany, and elsewhere, most of them small and most of them dependent on donations. Attested
The Universities Return
The small institutes worked by funding researchers inside respected universities and hospitals, rather than by building laboratories of their own, so that the results would stand on established ground. It worked. In 2006 a team at a large American medical school, reported to be the first to win approval to give psilocybin to volunteers who had never taken a psychedelic, published the landmark study described in From Sacrament to Contraband. Attested
That team has since become a dedicated center, which calls itself the largest psychedelic research center in the world and lists more than a hundred and fifty published studies, on subjects from addiction and depression to eating disorders and obsessive-compulsive disorder. Attested The institute of 1993 reports that researchers affiliated with it wrote seventeen of the twenty-seven most-cited papers on the classic psychedelics. We record that figure as much for what it says about how small this field long was as for what it says about the quality of the work.
Other universities followed. There are now research centers in London, in California, and elsewhere; a center at an American university that pairs psychiatry with spiritual care, described in The Chaplain's Chair; a contemplative university in Colorado with its own center for psychedelic studies; and a program at a divinity school devoted to the religious traditions that seek to carry people beyond ordinary consciousness. Attested A graduate institute in California founded a center in 2015 to train psychotherapists for this work, and training programs for clinicians have multiplied since. Attested A nonprofit medical research institute in the American Midwest has taken psilocybin for depression toward the final phase of trials, and has begun first trials of a second compound. Attested
Who Pays for the Questions
For most of the revival, the money came from private donors, many of them giving modest sums. The institute of 1993 says plainly that it is not an endowed foundation and depends on continuous giving, and it argues that these substances need independently funded research to find their proper place in medicine. Attested
In the last decade commercial investment has arrived in force, and with it a new vocabulary of markets and industry. An international body representing the wellness industry now keeps an initiative on psychedelics and healing, whose published trend report speaks of a "dramatic renaissance" driven by research, changing attitudes, and "growing political and financial support." Attested
Money is not wicked, but it has a direction. A donor, a company, and a government each want something from a study, and the questions that get asked are the questions someone will pay to answer. Ask of any finding who paid for it. See Reading the Research.
A Setback, Honestly Told
In June 2024 an advisory committee to the United States drug regulator voted against the effectiveness of MDMA-assisted therapy for post-traumatic stress, and that summer the regulator declined to approve it. Attested Its sponsors had worked toward that day for decades.
Researchers sympathetic to the field drew a sober lesson: future trials must follow "the most rigorous methods," and public feeling about psychedelics should become "more balanced and nuanced." Attested We count the episode as a sign of health. A field that can be told no, and can answer by doing better work, is a field growing up.
Where Things Stand
- Under United States federal law, psilocybin therapy is available only within approved clinical trials, though a few states have built regulated programs of their own. Ketamine, an anesthetic with dissociative and psychedelic effects, is the only such medicine that may be prescribed there outside a trial. Attested
- A few other countries have opened narrow doors for supervised medical use. Most have not. In most of the world no classic psychedelic is an approved medicine, and its safety and effectiveness for treating any condition have not been established to the standard regulators require. Attested
- Research continues into consciousness itself, into spirituality, into the brain, and into harms as well as benefits. Some research centers now run clinics for people who struggle in the weeks and months after a psychedelic experience. Attested
- The most careful voices in the field still warn that safety "has not been demonstrated" outside a structured clinical setting. That phrase comes not from a critic but from one of the revival's oldest funders. Attested
The return of these substances to the laboratory has been slower, more careful, and more argued over than either their champions or their critics predicted. That is to its credit. Read news of it as you would read news of any young field: with interest, with patience, and with the questions in Reading the Research.